image
Healthcare - Biotechnology - NASDAQ - US
$ 11.19
-5.65 %
$ 472 M
Market Cap
-3.79
P/E
CASH FLOW STATEMENT
-76.4 M OPERATING CASH FLOW
12.77%
-953 K INVESTING CASH FLOW
-89.91%
117 M FINANCING CASH FLOW
20.38%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis UroGen Pharma Ltd.
image
Net Income -102 M
Depreciation & Amortization 1.7 M
Capital Expenditures -194 K
Stock-Based Compensation 9.34 M
Change in Working Capital 3.34 M
Others 14.8 M
Free Cash Flow -76.6 M

Cash Flow

Millions
Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017 Dec-2016 Dec-2015 Dec-2014 Dec-2013
OPERATING CASH FLOW
Net Income (102.2) (109.8) (110.8) (128.5) (105.1) (75.7) (20.0) (1.9) (12.7) (4.5) (3.3)
Depreciation & Amortization 1.7 1.8 1.8 2.0 1.3 0.4 0.2 0.2 0.1 30 K 18 K
Deferred Income Tax 0 0 15.3 0.4 (0.6) 0 0 0 0.2 0 0
Stock Based Compensation 9.3 10.6 23.1 28.0 30.0 30.6 6.3 2.0 0.4 0.3 0.5
Other Operating Activities 11.5 16.1 (1.2) (1.5) (0.9) 100 K 0.2 2.7 4.1 0.2 0.2
Change in Working Capital 3.3 (6.3) (13.1) (6.4) 4.3 7.2 3.8 1.2 0.6 (0.2) 13 K
Cash From Operations (76.4) (87.6) (84.9) (105.9) (71.0) (37.3) (9.6) 4.2 (7.2) (4.1) (2.6)
INVESTING CASH FLOW
Capital Expenditures (0.2) (0.3) (0.8) (1.2) (0.3) (0.6) (0.3) (0.7) (0.3) 24 K 57 K
Other Items (0.8) 1.3 4.8 94.5 (145.3) 35.8 (36.1) 98 K 0 23 K 32 K
Cash From Investing Activities (1.0) 1.1 4.1 93.2 (145.6) 35.3 (36.4) (0.8) (0.3) 1 K 89 K
FINANCING CASH FLOW
Common Stock Repurchased 0 0 0 0 0 0 0 0 0 0 0
Total Debt Repaid 0 95.8 0 0 0 0 0 0 0 0.6 0
Dividends Paid 0 0 0 0 0 0 0 0 0 0 0
Other Financing Activities 49.6 1.4 72.3 0.7 3.6 2.2 0.7 9 K 21.6 4.3 3.5
Cash From Financing Activities 116.9 97.1 72.3 16.5 165.2 66.4 61.6 9 K 21.6 5.0 3.5
CHANGE IN CASH
Net Change In Cash 39.6 10.6 (8.5) 3.9 (51.4) 64.4 15.6 3.4 14.1 0.8 0.8
FREE CASH FLOW
Free Cash Flow (76.6) (87.8) (85.6) (107.1) (71.3) (37.9) (9.8) 3.5 (7.5) (4.1) (2.6)